An Advocate General to the European Court of Justice (ECJ) has recently argued that the European Commission’s antitrust enforcement against Illumina, a prominent genomics company, emanated from a misinterpretation of regulations. The official’s argument centers around the perceived overstep by the Commission in disallowing mergers that don’t meet specific revenue thresholds.
This prospective ECJ decision could have significant implications for the EU antitrust watchdog’s ability to regulate corporate mergers. Specifically, the ruling could jeopardize its capacity to investigate other cases that involve mergers falling short of the Commission’s revenue criteria.
It’s critical to note that the details surrounding this development remain under lock due to the paywall of the original article. More comprehensive insights into this ongoing legal discourse can be obtained via a paid subscription or by purchasing the individual article. To access the full article, click here.